DRTE Dendrite International (MM)

Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended as of October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering an aggregate of 40,000 shares of common stock were granted to one non-executive officer employee on November 1, 2006; options covering an aggregate of 7,500 shares were granted to one non-executive officer employee on October 30, 2006; options covering an aggregate of 40,000 shares of common stock were granted to three non-executive officer employees on October 23, 2006; and options covering an aggregate of 60,000 shares were granted to one non-executive officer employee on September 25, 2006. All such option grants were made under the Company's New Hire Authorization as inducements to entering into employment with the Company. All options granted include a ten-year duration and an exercise price equal to the closing price of Dendrite's stock on the business day immediately preceding the date of grant. The vesting schedule for the options is as follows: (i) twenty-five percent (25%) of the options shall first become exercisable on the first anniversary of date of grant and (ii) the remaining seventy-five percent (75%) shall become exercisable pro rata over the following three (3) year period, on a monthly basis, commencing on the first anniversary of the date of grant and ending on the fourth anniversary of the date of grant. About Dendrite Founded in 1986, Dendrite International, Inc. enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite� is a registered trademark of Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with our largest customer's plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing strategic options and with any transaction occurring or being consummated at any subsequent time. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K under "Factors That May Affect Future Results" and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any outlook and other forward-looking information is as of the date of this release only. At any such time in the future as the Company may provide revenue, earnings and other outlook information, prior related outlook should no longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur. Pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended as of October 14, 2003, Dendrite International, Inc. (NASDAQ: DRTE) today announced that stock options covering an aggregate of 40,000 shares of common stock were granted to one non-executive officer employee on November 1, 2006; options covering an aggregate of 7,500 shares were granted to one non-executive officer employee on October 30, 2006; options covering an aggregate of 40,000 shares of common stock were granted to three non-executive officer employees on October 23, 2006; and options covering an aggregate of 60,000 shares were granted to one non-executive officer employee on September 25, 2006. All such option grants were made under the Company's New Hire Authorization as inducements to entering into employment with the Company. All options granted include a ten-year duration and an exercise price equal to the closing price of Dendrite's stock on the business day immediately preceding the date of grant. The vesting schedule for the options is as follows: (i) twenty-five percent (25%) of the options shall first become exercisable on the first anniversary of date of grant and (ii) the remaining seventy-five percent (75%) shall become exercisable pro rata over the following three (3) year period, on a monthly basis, commencing on the first anniversary of the date of grant and ending on the fourth anniversary of the date of grant. About Dendrite Founded in 1986, Dendrite International, Inc. enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite(R) is a registered trademark of Dendrite International, Inc. FORWARD LOOKING INFORMATION: This document contains forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with our largest customer's plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing strategic options and with any transaction occurring or being consummated at any subsequent time. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K under "Factors That May Affect Future Results" and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any outlook and other forward-looking information is as of the date of this release only. At any such time in the future as the Company may provide revenue, earnings and other outlook information, prior related outlook should no longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur.